-
Something wrong with this record ?
Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates
HM. Lee, R. Andrys, J. Jonczyk, K. Kim, AG. Vishakantegowda, D. Malinak, A. Skarka, M. Schmidt, M. Vaskova, K. Latka, M. Bajda, YS. Jung, B. Malawska, K. Musilek
Language English Country Great Britain
Document type Journal Article
NLK
Directory of Open Access Journals
from 2017
PubMed Central
from 2017
Taylor & Francis Open Access
from 2002-01-01
Medline Complete (EBSCOhost)
from 2007-02-01
- MeSH
- Acetylcholinesterase metabolism MeSH
- Butyrylcholinesterase metabolism MeSH
- Quinolinium Compounds chemical synthesis chemistry pharmacology MeSH
- Cholinesterase Inhibitors chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Molecular Structure MeSH
- Pyridinium Compounds chemical synthesis chemistry pharmacology MeSH
- Recombinant Proteins metabolism MeSH
- Molecular Docking Simulation MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The pyridinium-2-carbaldoximes with quinolinium carboxamide moiety were designed and synthesised as cholinesterase reactivators. The prepared compounds showed intermediate-to-high inhibition of both cholinesterases when compared to standard oximes. Their reactivation ability was evaluated in vitro on human recombinant acetylcholinesterase (hrAChE) and human recombinant butyrylcholinesterase (hrBChE) inhibited by nerve agent surrogates (NIMP, NEMP, and NEDPA) or paraoxon. In the reactivation screening, one compound was able to reactivate hrAChE inhibited by all used organophosphates and two novel compounds were able to reactivate NIMP/NEMP-hrBChE. The reactivation kinetics revealed compound 11 that proved to be excellent reactivator of paraoxon-hrAChE better to obidoxime and showed increased reactivation of NIMP/NEMP-hrBChE, although worse to obidoxime. The molecular interactions of studied reactivators were further identified by in silico calculations. Molecular modelling results revealed the importance of creation of the pre-reactivation complex that could lead to better reactivation of both cholinesterases together with reducing particular interactions for lower intrinsic inhibition by the oxime.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018340
- 003
- CZ-PrNML
- 005
- 20221025122841.0
- 007
- ta
- 008
- 210728s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14756366.2020.1869954 $2 doi
- 035 __
- $a (PubMed)33467931
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Lee, Hyun Myung $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
- 245 10
- $a Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates / $c HM. Lee, R. Andrys, J. Jonczyk, K. Kim, AG. Vishakantegowda, D. Malinak, A. Skarka, M. Schmidt, M. Vaskova, K. Latka, M. Bajda, YS. Jung, B. Malawska, K. Musilek
- 520 9_
- $a The pyridinium-2-carbaldoximes with quinolinium carboxamide moiety were designed and synthesised as cholinesterase reactivators. The prepared compounds showed intermediate-to-high inhibition of both cholinesterases when compared to standard oximes. Their reactivation ability was evaluated in vitro on human recombinant acetylcholinesterase (hrAChE) and human recombinant butyrylcholinesterase (hrBChE) inhibited by nerve agent surrogates (NIMP, NEMP, and NEDPA) or paraoxon. In the reactivation screening, one compound was able to reactivate hrAChE inhibited by all used organophosphates and two novel compounds were able to reactivate NIMP/NEMP-hrBChE. The reactivation kinetics revealed compound 11 that proved to be excellent reactivator of paraoxon-hrAChE better to obidoxime and showed increased reactivation of NIMP/NEMP-hrBChE, although worse to obidoxime. The molecular interactions of studied reactivators were further identified by in silico calculations. Molecular modelling results revealed the importance of creation of the pre-reactivation complex that could lead to better reactivation of both cholinesterases together with reducing particular interactions for lower intrinsic inhibition by the oxime.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a butyrylcholinesterasa $x metabolismus $7 D002091
- 650 _2
- $a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a pyridinové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D011726
- 650 _2
- $a chinolinové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D011806
- 650 _2
- $a rekombinantní proteiny $x metabolismus $7 D011994
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Andrys, Rudolf $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Jonczyk, Jakub $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
- 700 1_
- $a Kim, Kyuneun $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
- 700 1_
- $a Vishakantegowda, Avinash G $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
- 700 1_
- $a Malinak, David $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Skarka, Adam $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Schmidt, Monika $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic $7 xx0278043
- 700 1_
- $a Vaskova, Michaela $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Latka, Kamil $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
- 700 1_
- $a Bajda, Marek $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
- 700 1_
- $a Jung, Young-Sik $u Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea $u Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
- 700 1_
- $a Malawska, Barbara $u Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
- 700 1_
- $a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- 773 0_
- $w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 36, č. 1 (2021), s. 437-449
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33467931 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20221025122839 $b ABA008
- 999 __
- $a ok $b bmc $g 1689480 $s 1138784
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 36 $c 1 $d 437-449 $e - $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
- LZP __
- $a Pubmed-20210728
